James P. O'Connor1,2, Gordon C. Jayson2, Alan Jackson1, Chris J. Rose1, Claire L. Mitchell2, Yvonne Watson1, Caleb Roberts1, Sue Cheung1, Giovanni A. Buonaccorsi1, Andrew R. Clamp2, Jurgees Hasan2, Lynn Hope2, Karen Davies1, Olivia del Puerto3, Geoff J. Parker1
1Imaging Science & Biomedical Engineering, University of Manchester, Manchester, UK; 2Medical Oncology, Christie Hospital, Manchester, UK; 3Roche Products Ltd, Welwyn Garden City, UK
We provide comprehensive data to define the sequence, magnitude and duration of anti-vascular effects induced by bevacizumab in a study of patients with colorectal cancer liver metastases evaluated using DCE-MRI. We demonstrate statistically signifcant reduction in blood plasma volume and enhancing fraction within 48 hours that lead to resolution of oedema and tumour shrinkage. The study highlights the importance of (1) optimising measurement timing in quantitative imaging studies employed in clinical trials and (2) performing multi-parameter DCE-MRI data analysis.